Data from a single-center registry shines light on 20 years of trends in first-line, biologic disease-modifying anti-rheumatic drug prescriptions for patients with rheumatoid arthritis.
Search results for: rituximab
Updates in Pediatric Lupus: Experts Discuss Advances in Lupus Nephritis Treatments, Monogenic Lupus & More
PRSYM—At the 2021 Pediatric Rheumatology Symposium (PRSYM), a session on lupus provided a robust discussion of recent advances in lupus treatments and genetic discoveries in pediatric rheumatology. Lupus Nephritis The first speaker was Shaun Jackson, MD, PhD, a pediatric nephrologist and rheumatologist and associate professor at Seattle Children’s. His presentation focused on state-of-the-art treatments in…
Vasculitis Guidelines in Focus, Part 1: The Guideline Project
Sharon A. Chung, MD, MAS, director of the vasculitis clinic at the University of California, San Francisco, served as the principal investigator of the overall vasculitis guideline effort and talks about the process here.
COVID-19 Vaccine Efficacy & Safety Discussed at Town Hall
At a recent ACR town hall, panelists described immune responses and side effects of COVID-19 vaccination in patients with rheumatic disease, along with ways to leverage monoclonal antibody treatments, especially in light of virus variants.
International Study Finds Colchicine Promising as Outpatient Treatment for COVID-19
One of the oldest treatment options in rheumatology, colchicine, may be an effective and inexpensive treatment to prevent complications in non-hospitalized patients with COVID-19, particularly in men, according to the results of large global study.
2 Cases of SLE-Associated Diffuse Alveolar Hemorrhage
Pulmonary manifestations in patients with systemic lupus erythematosus (SLE) include pleuritis, acute pneumonitis, interstitial lung disease, pulmonary arterial hypertension, shrinking lung syndrome and diffuse alveolar hemorrhage (DAH). DAH is a rare, but devastating, complication of SLE, with high mortality rates. The incidence of DAH in SLE ranges from 0.6% to 5.4%, but the mortality rate…
FDA’s Arthritis Advisory Committee Narrowly Endorses Avacopan Approval
On May 6, the U.S. Food & Drug Administration’s (FDA’s) Arthritis Advisory Committee narrowly voted in support of avacopan, a C5a receptor inhibitor, for the treatment of adult patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Although the panelists were excited about the possibility of a steroid-sparing therapy, some raised questions about whether results from…
Updates in Juvenile Dermatomyositis: Pathogenesis & Patient Care
Experts provided an update on juvenile dermatomyositis, discussing patient care, treatment options and the pathogenesis of disease.
The ACR/Vasculitis Foundation Release Three New Guidelines for Treatment of Vasculitis
ATLANTA—The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis. Vasculitis is a group of about 20 rare diseases that have inflammation of blood vessels in common, which can restrict blood flow and damage vital organs. The three guidelines cover…
Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations
Hesitancy about COVID-19 vaccination persists nationwide, although it varies among regions and sociodemographic groups.
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 45
- Next Page »